Introduction
============

Renal cell carcinoma (RCC) accounts for approximately 2% of all malignancies in adults [@B1]. The majority of RCC cases are the clear cell RCC (ccRCC) subtype. Despite extensive efforts towards improving diagnosis and treatment strategies for ccRCC, more than 30% of patients present with metastatic disease at diagnosis and 20-40% of RCC patients who undergo radical surgical procedures eventually develop metastasis [@B2]. Important prognostic models for ccRCC, including SSIGN [@B3], [@B4], ccA/ccB [@B5], clearcode34 [@B6], and S3-score [@B1], have provided insight into the molecular predictors of poor outcome in ccRCC. Notably, members of the soluble carrier (SLC) gene family are involved in each of these models [@B1], [@B6].

To date, a total of 378 SLC members categorized into 51 families have been identified [@B7]. SLC family genes encode passive transporters, ion coupled transporters and exchangers, and represent a major portion of human transporter-related genes [@B8]. Rapidly proliferating cancer cells require enhanced anabolic pathways to support cell mitosis [@B9]. Consistent with the increased amino acid and glucose uptake in cancer cells, elevated expression of nutrient transporter proteins is associated with aggressive and highly malignant cancers [@B10]. Despite the important role of amino acids, glucose and iron transporters in cancer, the SLC family has not been well examined in ccRCC. In the present study, we analyzed the potential prognostic association of SLC expression in a ccRCC cohort from The Cancer Genome Atlas (TCGA) and validated the results in the Fudan University Shanghai Cancer Center (FUSCC) cohort, another Asian cohort.

Material and Methods
====================

Patients and samples
--------------------

This study was approved by the Ethical Committee of Fudan University Shanghai Cancer Center (FUSCC), and written informed consent was obtained from all patients before the study. Expression of SLC family members (IlluminaHiSeq) and metadata of the ccRCC patient TCGA cohort were downloaded from the Cancer Genomics Browser of the University of California Santa Cruz (<https://genome-cancer.ucsc.edu/>). A total of 364 SLC members were included in the analysis. The detail annotations of these genes have been reviewed in the website of bioparadigms (<http://slc.bioparadigms.org>). In the TCGA ccRCC cohort, only patients with fully characterized ccRCC tumors, intact overall survival (OS), and disease-free survival (DFS) data, and complete RNAseq data were included. OS was defined as time from the date of diagnosis to the date of death or last follow-up. Patients without events or death at the time of the last follow-up were recorded as censored. Sixteen patients were excluded because of non-ccRCC pathology reported in a previous study [@B1]. A final 509 patients were enrolled in the present study. Demographic and clinical parameters, including age, sex, tumor size, TNM, Fuhrman grade, AJCC stage, laterality and OS were collected.

In the FUSCC validation cohort, a total of 178 ccRCC patients from 2007 to 2011 who underwent radical nephrectomy or nephron-sparing nephrectomy were retrospectively enrolled. Tissue samples were collected once resected and stored at -70°C in the tissue bank of FUSCC. A central review of pathology was performed by an experienced pathologist. Clinicopathological characteristics were obtained from electronic records. Patients were regularly followed up by telephone, mail, or in the clinic once every 3 months.

SLC gene expression in sunitinib resistance
-------------------------------------------

Two open source, RNA expression data sets on sunitinib response were downloaded from the GEO database (GSE64052 and GSE65615) [@B11], [@B12]. Gene expression data and metadata were processed by MeV software [@B13]. The samples were separated into sunitinib-treated and untreated groups and t tests were used to compare differences.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis
-------------------------------------------------------------------------------

Total RNA was isolated from 178 frozen ccRCC tumors from the FUSCC validation cohort using TRIzol^®^ reagent (15596-026, Invitrogen, Carlsbad, CA). The PrimeScript RT reagent kit (K1622, Thermo Scientific, Lithuania) was used to synthesize first-strand cDNA. SYBR Green real-time PCR assays were performed using an ABI 7900HT (Applied Biosystems, USA). The expression levels of SLCs were normalized to the level of β-actin [@B14]. The primers for qRT-PCR analysis were synthesized by Sangon (Shanghai, People\'s Republic of China). The primers sequences are as follows: *SLC10A2* (ASBT), forward primer, 5′-TGGGTTTCTTCCTGGCTAGACT-3′ and reverse primer, 5′-TGTTCTGCATTCCAGTTTCCAA-3′ [@B15]; and β-actin: forward primer: 5′-AGCGAGCATCCCCCAAAGTT-3′, reverse primer: 5′-GGGCACGAAGGCTCATCATT-3′.

Statistical analysis
--------------------

R project and SPSS 17.0 (SPSS, Chicago, Illinois) were used to perform statistical analysis. Survival curves were constructed using the Kaplan-Meier method and plotted with Graphpad Prism 6. Log-rank tests were used to assess the differences between the groups. Univariate and multivariate Cox proportional HR of all SLCs expression and OS for patients with ccRCC in the TCGA cohort were analyzed. We used a paired t test to compare tumor and normal SLC expression data. A t test was used to compare expression data between sunitinib-resistant and non-resistant groups. T test was used compare continuous variables while χ^2^ test was applied in category variables. A two-sided P-value \< 0.05 was considered as statistically significant.

Results
=======

Demographic and clinical characteristics of ccRCC patients in TCGA and FUSCC cohorts
------------------------------------------------------------------------------------

The workflow of this study is shown in Figure [1](#F1){ref-type="fig"}. The TCGA cohort comprised 328 (64.4%) male patients and 181 (35.6%) female patients. The median age of the 509 ccRCC patients was 61 years, with a range from 26 to 90 years. TNM, tumor size, nuclear grade, stage, laterality are shown in Table [1](#T1){ref-type="table"}. The median follow-up time was 35.8 months and 162 patients died during follow-up.

The FUSCC cohort comprised 122 (70.3%) male patients and 56 (29.7%) female patients. The median age of the 178 ccRCC patients was 56 years, with a range from 25 to 86 years. The detailed clinical data are shown in Table [1](#T1){ref-type="table"}. The median follow-up time was 50.2 months and 40 patients died during follow-up.

Screening candidate prognostic genes in the SLC family in the TCGA cohort
-------------------------------------------------------------------------

We first conducted univariate Cox proportion hazard ratio analysis for screening 364 SLC family members as well as clinicopathological variables as prognostic factors. Age, laterality, American Joint Committee on Cancer (AJCC) stage, Fuhrman grade, pathological T stage, M stage, tumor necrosis, preoperative white blood cell count, and 199 SLC genes were significantly associated with overall survival (OS) of ccRCC patients in the TCGA cohort (all *P* \< 0.05; Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Only variables that were significantly associated with prognosis in previous univariate Cox regression (*P*\< 0.01), which included a total of 165 SLC genes, were used to build a reduced multivariate model. Backward stepwise multivariate Cox regression demonstrated that in the final model, age (hazard ratio \[HR\]=1.045, 95% confidence interval \[CI\]: 1.025-1.065), T stage (HR=0.110, 95% CI: 0.059-0.206), AJCC stage (HR=16.099, 95% CI: 7.687-33.718), tumor necrosis (HR=2.676, 95% CI: 1.438-4.980), and 61 SLC members were independent prognostic factors (all *P* \< 0.05; Table [2](#T2){ref-type="table"}).

Comparison of prognostic SLC gene expressions in tumor and adjacent kidney tissues
----------------------------------------------------------------------------------

71 paired normal and tumor tissues in TCGA database were enrolled in the following analysis. A paired t test showed that among the 61 prognostic SLC genes, 26 were downregulated and 23 were upregulated in tumor tissues compared with normal kidney tissues (all *P* \< 0.05; Table [3](#T3){ref-type="table"}). Twelve genes were upregulated in tumor tissues and associated with poor prognosis (Table [3](#T3){ref-type="table"}). Gene ontology analysis showed that these genes were associated with energy metabolism and small molecular transportation (detailed in Supplementary Table [2](#SM1){ref-type="supplementary-material"}). Eleven upregulated SLC genes were associated with favorable outcome of ccRCC (Table [3](#T3){ref-type="table"}). The gene ontology analyses are detailed in Supplementary Table [3](#SM1){ref-type="supplementary-material"}.

SLC gene expression in sunitinib resistance
-------------------------------------------

We next analyzed SLC gene expression in sunitinib resistance by analyzing two open source, RNA expression data sets on sunitinib response from the Gene Expression Omnibus (GEO) database (GSE64052 and GSE65615) as described in Materials and Methods. In a previous study by Zhang [@B11], human RCC cell lines were implanted into the flanks of nude mice to establish a xenograft mouse model and mice were treated with tyrosine kinase inhibitors (TKIs; sunitinib or sorafenib). Gene expression analysis was performed using the GPL570 platform. Two groups of tumors (14 TKI treated and 15 untreated) were compared by t test. Mean values were used in cases in which different probes represent a single gene. The results showed that *SLC25A37* was upregulated in TKI-treated xenografts compared with untreated tumors, while eight genes, *SLC10A2, SLC17A1, SLC22A2, SLC25A19, SLC25A37, SLC38A6, SLC40A1,*and *SLC44A4*, were decreased in TKI-treated xenografts (all *P* \< 0.05; Supplementary Table [3](#SM1){ref-type="supplementary-material"}).

Stewart et al. [@B12] performed RNAseq in 75 sunitinib-treated and 47 untreated ccRCC samples to investigate the effect of VEGF targeted therapy (sunitinib) on metastatic ccRCC. Our analyses revealed that 12 genes were significantly increased in sunitinib-treated samples compared with untreated samples (all *P* \< 0.05; Supplementary Table [3](#SM1){ref-type="supplementary-material"}). Eight genes were decreased in sunitinib-treated samples (all *P* \< 0.05; Supplementary Table [3](#SM1){ref-type="supplementary-material"}).

*SLC10A2* expression is a prognostic factor for OS in the FUSCC cohort
----------------------------------------------------------------------

Evaluation of both datasets described above revealed that only *SLC10A2* was significantly downregulated in TKI-treated samples. Our previous results showed that *SLC10A2*was upregulated in ccRCC compared with adjacent kidney tissues in paired TCGA samples. High *SLC10A2* expression was associated with good prognosis of ccRCC. We divided the TCGA cohort into low- and high-expression groups according to the median *SLC10A2*expression level. In a multivariate regression model, tumor stage (odds ratio \[OR\]=0.545, 95% CI: 0.398-0.745) and necrosis (OR=0.352, 95% CI: 0.195-0.634) were associated with *SLC10A2* expression (Table [4](#T4){ref-type="table"}). Therefore, we next validated the prognostic predictor role of *SLC10A2* in the FUSCC cohort. A total of 37 patients deceased with a mean follow up time 87.2 months. In multivariate Cox regression model, we found that stage (HR=4.654, 95%CI: 2.029-10.674) and low *SLC10A2* expression (HR=0.432,95%CI: 0.204-0.915) were associated with poor prognosis for OS (Table [5](#T5){ref-type="table"}). We divided the cohort into low- and high-expression groups according to the median expression level of *SLC10A2* and the Kaplan-Meier curves are shown in Figure [2](#F2){ref-type="fig"}.

Discussion
==========

In the present study, we comprehensively demonstrated that gene expressions of SLC family members were correlated with the outcome of ccRCC patients. A total of 364 SLC members categorized into 49 families were investigated in this study. Our results showed that 61 of these genes were independent prognostic factors for OS of ccRCC patients. Among the 61 genes, we found that 49 showed differential expression between benign and malignant tissues. Moreover, *SLC10A2* was associated with TKI response in two separate studies. We validated this finding in the FUSCC cohort to confirm that *SLC10A2* was an independent predictor of ccRCC outcome.

SLCs comprise a superfamily encoding transporter-related genes. Transporters are the gatekeepers for all cells, controlling uptake and efflux of crucial metabolism compounds [@B8]. It has been well established that tumor cells have different metabolism patterns compared with normal tissues. For instance, ^18^F-FDG has been used as a marker of tumors for enhanced glucose uptake of tumor cells [@B16].

In the multivariate analysis of TCGA and FUSCC cohort, significant parameters were different. Such as T stage and necrosis in TCGA and only T stage in FUSCC. We did not include necrosis in FUSCC analysis because we cannot fully access the necrosis criteria of TCGA. In analysis of TCGA, more parameters were included, this may also affect the results.

Our results showed that *SLC9A5, SLC10A5, SLC12A7, SLC16A8, SLC18A3, SLC25A14, SLC25A28, SLC25A37, SLC35E4, SLC38A10, SLC38A6,*and *SLCO2A1* were upregulated in ccRCC and associated with poor prognosis, indicating that these genes may represent possible oncogenes that could serve as therapeutic targets of ccRCC. No reports have been published on the association between the above genes and prognosis of ccRCC until now. These genes are dysregulated in ccRCC and have multiple functions regarding amino acid, nucleoside, inorganic, and organic anion transduction and as mitochondrial carriers [@B17]. SLCs have been reported to be associated with chemotherapeutic drug transport in pancreatic, colorectal, and hepatocyte cancers [@B18]-[@B20]. Further study on drugs that modulate SLCs may help to further the development of anti-cancer drugs.

In our analyses of sunitinib resistance in ccRCC, we identified *SLC10A2* as a possible target. *SLC10* is an influx transporter of bile acids, steroidal hormones, various drugs, and several other substrates [@B21]. *SLC10A2*, also called apical sodium-dependent bile acid transporter (ASBT) [@B22], is highly expressed in the intestine and participates in bile acid recycling [@B23]. In proximal tubule cells, ASBT facilitates bile acid reclaiming from primary urine [@B21]. Previous studies showed that ASBT is regulated by the glucocorticoid receptor [@B24], vitamin D receptor, peroxisome proliferator-activated receptor-α [@B25], and caudal-type homeobox-1 and -2 [@B26]. ASBT is also upregulated by vitamin D, glucocorticoids, and ampicillin and inhibited by statins and dihydropyridine calcium channel blockers [@B21]. Because ASBT expression was associated with prognosis and sunitinib response, and given that therapeutic drugs regulating *ASBT* already exist, further research on this gene and tumor phenotypes of ccRCC is warranted.

Although previous literature has shown that the SLC family plays an important role in the prognosis of various cancers [@B18], [@B19], no study has examined their role in RCC. Our work indicates a correlation between ccRCC outcome and this gene family. However, the underlying mechanism still remains unclear and should be the subject of future studies.

A major strength of the present study is that the data were obtained from two large populations with a long follow-up. The TCGA ccRCC cohort is not a clinical trial population, with diminished selection bias, and thus could be more representative as a "real-world" population. Another strength is that comprehensive analysis of SLC in TKI treatment was conducted in two open source GEO databases.

However, certain limitations should be noted. The prognosis of ccRCC is affected by many factors such as tumor stage, operation performance, and response to TKI therapy. These factors could not all be included in the multivariate prognostic model. In particular, the TCGA cohort does not include information on TKI therapy. The two GEO data sets were acquired by different platforms with different experiment settings. Inconsistent results could thus not be simply considered as insignificant. The validation cohort has a smaller case numbers than TCGA cohort. Because we did not get such resources as TCGA group did to recruit more patients with RNA sequencing in a period of time. The mechanisms of *SLC10A2* were not included in this article. Further clinical study and/or meta-analyses are needed to confirm our results.

In conclusion, our results demonstrated that the expression of several SLCs predicted the clinical outcome of ccRCC patients. We found a considerable variability in the gene expression of SLC transporters between tumor and normal human kidney tissues. *SLC10A2* was identified as an independent prognostic factor of overall survival of ccRCC and *SLC10A2* expression was decreased in sunitinib-resistant ccRCC. Further studies investigating the role and mechanism of SLC transporters in ccRCC are needed.
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![Workflow of the experimental design and main procedures. To identify a robust prognostic of gene expression signature of SLCs in ccRCC, we used TCGA dataset of 509 samples as a discovery set. A list of 364 SLCs was brought into univariate and multivariate Cox hazard ratio model and 61 SLCs were independent prognostic factors of OS. They were compared in 71 paired normal and cancer tissue with paired t test. 26 were downregulated and 23 were upregulated in tumor tissues compared with normal kidney tissues. The 49 SLCs were compared in TKI-resistant versus non-resistant tissues in GEO database and only SLC10A2 were consistent with TKI-resistant status. At last, we used qRT-PCR validated SCL10A2 as a favorable predictors of OS in FUSCC cohort.](jcav08p2010g001){#F1}

![Kaplan-Meier plots of survival in the TCGA and FUSCC cohorts according to *SLC10A2* expression. A. Kaplan-Meier estimates of overall survival (OS) according to *SLC10A2* expression level in the TCGA cohort. B. Kaplan-Meier estimates of OS according to *SLC10A2* expression level in the FUSCC cohort.](jcav08p2010g002){#F2}

###### 

Clinicopathologial Characterisics of patients with ccRCC in TCGA and FUSCC cohort

  Variables                 TCGA cohort(N=509)   FUSCC cohort(N=178)   p^1^                       
  ------------------------- -------------------- --------------------- ------------------- ------ ------------
  Age, median(range)        61(26 to 90)                               56(25 to 86)               \<0.001^2^
  Gender                                                                                          0.360
  Male                      328                  64.4                  122                 68.5   
  Female                    181                  35.6                  56                  31.5   
  Tumor size, mean(range)   1.68(0.4 to 4.0)                           5.00(1.0 to 16.0)          \<0.001^2^
  Laterality                                                                                      0.270
  Left                      239                  47                    82                  46.1   
  Right                     269                  52.8                  94                  52.8   
  bilateral                 1                    0.2                   2                   1.1    
  Grade                                                                                           0.051
  1                         12                   2.4                   9                   5.1    
  2                         222                  43.6                  72                  40.4   
  3                         197                  38.7                  81                  45.5   
  4                         74                   14.5                  16                  9      
  Gx                        4                    0.8                   0                   0      
  pT                                                                                              \<0.001
  T1                        258                  50.7                  126                 70.8   
  T2                        63                   12.4                  23                  12.9   
  T3                        178                  35                    25                  14     
  T4                        10                   2                     4                   2.2    
  N                                                                                               \<0.001
  N0                        228                  44.8                  169                 94.9   
  N1                        17                   3.3                   2                   1.1    
  Nx                        264                  51.9                  7                   3.9    
  M                                                                                               \<0.001
  M0                        406                  79.8                  171                 96.1   
  M1                        78                   15.3                  6                   3.4    
  Mx                        25                   4.9                   1                   0.6    
  Stage                                                                                           \<0.001
  I                         253                  49.7                  125                 70.2   
  II                        51                   10                    20                  11.2   
  III                       125                  24.6                  25                  14     
  IV                        80                   15.7                  8                   4.5    

1 χ2 test or indicated otherwise.

2 t test.

TCGA, The Cancer Genome Atlas; FUSCC, Fudan University Shanghai Cancer Center

###### 

Multivariate Cox hazard ratio regression model of clinical parameters and soluble carrier super family expression in TCGA ccRCC cohort

  Parameters   HR       95%CI          P\*
  ------------ -------- -------------- -----------
  Age          1.045    1.025-1.065    **0.000**
  T            0.110    0.059-0.206    **0.000**
  M            0.365    0.133-1.002    0.050
  stage        16.099   7.687-33.718   **0.000**
  Necrosis     2.676    1.438-4.980    **0.002**
  SLC2A13      0.382    0.228-0.640    **0.000**
  SLC4A5       0.536    0.342-0.840    **0.007**
  SLC4A8       0.502    0.322-0.782    **0.002**
  SLC5A5       0.321    0.234-0.441    **0.000**
  SLC5A6       0.439    0.241-0.799    **0.007**
  SLC6A7       0.618    0.454-0.841    **0.002**
  SLC7A9       1.463    1.101-1.944    **0.009**
  SLC6A15      1.225    1.056-1.421    **0.007**
  SLC6A19      0.812    0.730-0.903    **0.000**
  SLC9A3R2     0.437    0.263-0.725    **0.001**
  SLC9A5       2.087    1.344-3.242    **0.001**
  SLC10A2      0.788    0.695-0.893    **0.000**
  SLC10A3      0.458    0.209-1.006    0.052
  SLC10A5      1.660    1.230-2.239    **0.001**
  SLC10A6      0.791    0.626-0.999    **0.049**
  SLC11A2      0.189    0.089-0.401    **0.000**
  SLC12A4      0.050    0.018-0.137    **0.000**
  SLC12A7      4.223    2.484-7.180    **0.000**
  SLC12A8      1.323    1.100-1.590    **0.003**
  SLC13A4      0.478    0.369-0.619    **0.000**
  SLC14A1      0.775    0.628-0.956    **0.017**
  SLC16A8      2.721    1.843-4.015    **0.000**
  SLC17A1      2.007    1.623-2.482    **0.000**
  SLC17A5      0.234    0.128-0.426    **0.000**
  SLC17A7      2.325    1.755-3.082    **0.000**
  SLC18A3      1.106    1.025-1.194    **0.009**
  SLC20A1      4.324    2.090-8.946    **0.000**
  SLC22A2      1.320    1.136-1.535    **0.000**
  SLC22A20     1.905    1.367-2.655    **0.000**
  SLC24A6      5.529    1.980-15.443   **0.001**
  SLC25A14     2.330    1.041-5.216    **0.040**
  SLC25A19     0.129    0.060-0.278    **0.000**
  SLC25A23     0.334    0.198-0.565    **0.000**
  SLC25A27     1.588    1.180-2.136    **0.002**
  SLC25A28     4.264    1.776-10.237   **0.001**
  SLC25A29     0.449    0.269-0.749    **0.002**
  SLC25A35     4.743    2.572-8.745    **0.000**
  SLC25A37     2.606    1.674-4.057    **0.000**
  SLC25A39     10.389   4.152-25.994   **0.000**
  SLC25A46     0.317    0.142-0.709    **0.005**
  SLC26A1      0.349    0.248-0.491    **0.000**
  SLC26A8      0.614    0.443-0.852    **0.003**
  SLC30A1      2.376    1.377-4.102    **0.002**
  SLC35A3      3.246    1.655-6.368    **0.001**
  SLC35B2      4.723    2.089-10.679   **0.000**
  SLC35B4      6.985    3.063-15.931   **0.000**
  SLC35D3      0.534    0.320-0.892    **0.016**
  SLC35E4      5.431    2.774-10.631   **0.000**
  SLC35F1      0.744    0.544-1.016    0.063
  SLC35F3      1.191    1.023-1.386    **0.025**
  SLC35F5      4.297    1.990-9.281    **0.000**
  SLC38A10     5.816    2.615-12.936   **0.000**
  SLC38A11     0.693    0.569-0.846    **0.000**
  SLC38A6      2.046    1.087-3.850    **0.027**
  SLC39A3      0.156    0.069-0.352    **0.000**
  SLC39A9      11.986   3.674-39.103   **0.000**
  SLC40A1      0.371    0.242-0.569    **0.000**
  SLC43A3      1.507    0.968-2.346    0.069
  SLC44A1      0.484    0.224-1.047    0.065
  SLC44A4      1.285    1.086-1.521    **0.003**
  SLC45A2      0.572    0.458-0.716    **0.000**
  SLC45A4      0.678    0.441-1.042    0.077
  SLC46A2      1.378    0.990-1.918    0.057
  SLC47A1      0.608    0.466-0.792    **0.000**
  SLCO2A1      2.505    1.697-3.700    **0.000**
  SLCO4C1      1.529    1.168-2.001    **0.002**
  SLCO5A1      0.617    0.455-0.835    **0.002**

\*Parameters that were significant (p\<0.01) in univariate cox regression model entered the multivariate model. Backward Cox regression procedure was used to build the multivariate model;

*P*\<0.05 were indicated as bold type

###### 

Comparision of ccRCC tumors versus adjacent normal tissues in SLCs

  Gene Name      Normal(N=71)   Tumor(N=71)   Fold change   *P*\*   Tumor expression   HR^a^       Survival association            
  -------------- -------------- ------------- ------------- ------- ------------------ ----------- ---------------------- -------- ------------
  SLC2A13        10.204         0.635         9.422         0.672   0.582              **0.000**   down regulated         0.382    favourable
  SLC4A5         5.558          0.598         6.246         0.669   1.610              **0.000**   upregulated            0.536    favourable
  SLC4A8         7.642          1.503         4.821         0.809   0.142              **0.000**   down regulated         0.502    favourable
  SLC5A5         0.385          0.479         0.807         0.731   1.341              **0.000**   upregulated            0.321    favourable
  SLC5A6         8.755          0.269         8.645         0.551   0.926              0.089       down regulated         0.439    favourable
  SLC6A15        2.694          1.299         1.313         2.319   0.384              **0.000**   down regulated         1.225    poor
  SLC6A19        9.841          3.900         6.768         3.642   0.119              **0.000**   down regulated         0.812    favourable
  SLC6A7         0.326          0.417         0.653         0.579   1.255              **0.000**   upregulated            0.618    favourable
  **SLC7A9**     7.693          3.520         8.114         1.797   1.339              0.384       upregulated            1.463    poor
  SLC9A3R2       11.025         0.527         10.640        1.071   0.766              **0.006**   down regulated         0.437    favourable
  **SLC9A5**     2.770          0.747         3.379         0.931   1.526              **0.000**   upregulated            2.087    poor
  SLC10A2        5.943          3.612         7.542         2.903   3.029              **0.001**   upregulated            0.788    favourable
  **SLC10A5**    3.207          0.969         3.588         1.381   1.303              **0.039**   upregulated            1.660    poor
  SLC10A6        1.647          0.824         4.115         1.348   5.532              **0.000**   upregulated            0.791    favourable
  SLC11A2        10.643         0.265         9.898         0.463   0.597              **0.000**   down regulated         0.189    favourable
  SLC12A4        10.279         0.377         10.773        0.472   1.408              **0.000**   upregulated            0.050    favourable
  **SLC12A7**    11.044         0.449         11.885        0.756   1.791              **0.000**   upregulated            4.223    poor
  SLC12A8        7.729          0.725         6.235         2.053   0.355              **0.000**   down regulated         1.323    poor
  SLC13A4        1.678          0.709         1.626         1.002   0.965              0.668       down regulated         0.478    favourable
  SLC14A1        9.823          1.744         6.655         1.440   0.111              **0.000**   down regulated         0.775    favourable
  **SLC16A8**    1.589          0.609         1.922         0.743   1.260              **0.003**   upregulated            2.721    poor
  SLC17A1        8.239          3.517         7.703         2.262   0.690              0.265       down regulated         2.007    poor
  SLC17A5        10.316         0.460         10.121        0.452   0.874              **0.014**   down regulated         0.234    favourable
  SLC17A7        3.830          0.756         2.589         0.970   0.423              **0.000**   down regulated         2.325    poor
  **SLC18A3**    0.126          0.219         1.733         2.561   3.047              **0.000**   upregulated            1.106    poor
  SLC20A1        9.739          0.819         9.347         0.546   0.762              **0.001**   down regulated         4.324    poor
  SLC22A2        12.165         0.830         11.981        1.703   0.880              0.406       down regulated         1.320    poor
  SLC22A20       1.668          0.665         1.267         1.093   0.757              **0.009**   down regulated         1.905    poor
  SLC24A6        9.610          0.560         9.401         0.510   0.866              **0.023**   down regulated         5.529    poor
  **SLC25A14**   6.558          0.226         6.819         0.473   1.199              **0.000**   upregulated            2.330    poor
  SLC25A19       7.333          0.451         7.597         0.618   1.201              **0.002**   upregulated            0.129    favourable
  SLC25A23       11.591         0.265         11.270        0.557   0.801              **0.000**   down regulated         0.334    favourable
  SLC25A27       6.012          0.722         5.426         1.157   0.666              **0.000**   down regulated         1.588    poor
  **SLC25A28**   8.857          0.223         9.194         0.449   1.264              **0.000**   upregulated            4.264    poor
  SLC25A29       9.428          0.516         7.762         0.758   0.315              **0.000**   down regulated         0.449    favourable
  SLC25A35       7.546          0.447         5.770         0.633   0.292              **0.000**   down regulated         4.743    poor
  **SLC25A37**   8.177          0.391         8.693         0.753   1.430              **0.000**   upregulated            2.606    poor
  SLC25A39       11.626         0.388         10.775        0.825   0.555              **0.000**   down regulated         10.389   poor
  SLC25A46       9.719          0.271         9.534         0.441   0.880              **0.002**   down regulated         0.317    favourable
  SLC26A1        7.260          1.512         7.080         1.480   0.883              0.447       down regulated         0.349    favourable
  SLC26A8        1.085          0.753         0.974         0.670   0.926              0.324       down regulated         0.614    favourable
  SLC30A1        9.423          0.496         8.738         0.797   0.622              **0.000**   down regulated         2.376    poor
  SLC35A3        9.031          0.347         8.450         0.584   0.668              **0.000**   down regulated         3.246    poor
  SLC35B2        10.440         0.311         10.409        0.442   0.979              0.630       down regulated         4.723    poor
  SLC35B4        9.897          0.338         9.776         0.414   0.919              0.054       down regulated         6.985    poor
  SLC35D3        0.106          0.236         0.121         0.254   1.010              0.736       upregulated            0.534    favourable
  **SLC35E4**    5.838          0.683         6.252         0.683   1.333              **0.000**   upregulated            5.431    poor
  **SLC35F3**    4.163          0.796         4.289         2.109   1.091              0.652       upregulated            1.191    poor
  SLC35F5        10.989         0.416         10.350        0.502   0.642              **0.000**   down regulated         4.297    poor
  **SLC38A10**   11.228         0.270         11.475        0.707   1.187              **0.005**   upregulated            5.816    poor
  SLC38A11       6.429          0.952         4.900         1.073   0.346              **0.000**   down regulated         0.693    favourable
  **SLC38A6**    7.186          0.500         7.535         0.629   1.274              **0.000**   upregulated            2.046    poor
  SLC39A3        8.554          0.394         8.042         0.723   0.701              **0.000**   down regulated         0.156    favourable
  SLC39A9        11.540         0.170         10.931        0.365   0.656              **0.000**   down regulated         11.986   poor
  SLC40A1        11.979         0.368         12.193        0.734   1.160              **0.014**   upregulated            0.371    favourable
  SLC44A4        10.762         0.714         7.992         1.768   0.147              **0.000**   down regulated         1.285    poor
  SLC45A2        1.580          0.779         2.314         1.551   1.664              **0.000**   upregulated            0.572    favourable
  SLC47A1        10.669         1.642         11.761        1.775   2.132              **0.000**   upregulated            0.608    favourable
  **SLCO2A1**    10.732         1.249         11.441        1.227   1.634              **0.001**   upregulated            2.505    poor
  **SLCO4C1**    11.011         0.531         11.150        1.221   1.101              0.325       upregulated            1.529    poor
  SLCO5A1        1.377          1.034         2.368         1.221   1.987              **0.000**   upregulated            0.617    favourable

\**P* paired t test, two side. *P*\<0.05 were indicated as bold type

^a^ Hazard ratio of overall survival

###### 

Multivariate regression analysis of clinicopathological paramters and SCL10A2 in TCGA cohort

  Variables    OR      95% CI          P
  ------------ ------- --------------- -----------
  Age          0.991   (0.975-1.007)   0.276
  Sex          1.261   (0.830-1.915)   0.277
  Grade        0.545   (0.398-0.745)   **0.000**
  Laterality   1.226   (0.827-1.817)   0.311
  Tumor size   0.694   (0.781-1.450)   0.694
  Necrosis     0.352   (0.195-0.634)   **0.001**
  AJCC Stage   0.881   (0.728-1.067)   0.196

Sex, female vs male. Laterality, left vs right.*P*\<0.05 were indicated as bold type. SCL10A2 were dichotomized as two group with median expression value.

###### 

Multivariate Cox hazard ratio regression model of clinical parameters and SLC10A2 in FUSCC ccRCC cohort

  Parameters   HR          95%CI            *P*\*
  ------------ ----------- ---------------- -------------
  Age          0.755       (0.347-1.639)    0.477
  T            1.042       (0.543-2.002)    0.901
  M            0.332       (0.062-1.768)    0.196
  Stage        **4.654**   (2.029-10.674)   **\<0.001**
  Necrosis     4.087       (0.701-23.824)   0.118
  SLC10A2      **0.432**   (0.204-0.915)    **0.028**

\**P*\<0.05 were indicated as bold type. T, M, were pathological stage, stage was AJCC stage. SLC10A2 were used -delta CT to beta-actin
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